Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Cefoperazone; Sulbactam; Sulperazone

Criteria

Inclusion Criteria:

• Male or female patient of age 18 years or older.

• Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

• Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.